Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

NCT03989466 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Recurrent T-Cell Prolymphocytic Leukemia
T-Cell Prolymphocytic Leukemia

Interventions

BIOLOGICAL: Alemtuzumab
DRUG: Itacitinib

Sponsor

M.D. Anderson Cancer Center